#United States #San Diego #Arthrosi Therapeutics #Gout Treatment #pozdeutinurad

Arthrosi Therapeutics Highlights Key Presentations at EULAR 2025

Arthrosi Therapeutics, Inc., a prominent biotechnology firm headquartered in San Diego, has made significant strides in the treatment of gout, announcing its participation in the European Alliance of Associations for Rheumatology (EULAR) Congress 2025. This prominent event, scheduled to take place from June 11th to 14th in Barcelona, Spain, will serve as a platform for the company to present its research findings concerning its novel drug candidate, pozdeutinurad (AR882).

About the Presentations

Arthrosi will be showcasing two key presentations at the congress:

1. Safety and Tolerability of Pozdeutinurad (AR882): This oral presentation will delve into the long-term effects and treatment safety of pozdeutinurad for patients suffering from chronic gouty arthritis and subcutaneous tophi. The session, led by Dr. Robert Keenan, Chief Medical Officer of Arthrosi, will take place on Friday, June 13, 2025, at 10:30 AM CEST.

2. Sustained Efficacy of Pozdeutinurad (AR882): The second presentation will be a poster session focused on the long-term effectiveness of pozdeutinurad in treating chronic gouty arthritis, scheduled for Saturday, June 14, 2025, from 10:00 AM to 3:00 PM CEST.

The Gout Landscape

Gout remains a significant health concern, with approximately 13 million individuals diagnosed in the United States alone, including around 2 million with tophaceous gout. This form of inflammatory arthritis drastically impacts the quality of life, leading to debilitating pain and mobility challenges as uric acid crystals form in the joints and soft tissues. The kidneys play an integral role in managing uric acid levels, and in many patients, the underexcretion of uric acid can exacerbate the condition, resulting in painful flare-ups and chronic symptoms.

Pozdeutinurad's Approach

Arthrosi Therapeutics aims to tackle these challenges with pozdeutinurad, a next-generation URAT1 inhibitor that exhibits powerful potential in reducing serum urate levels and resolving tophi in patients managing gout. Early-phase clinical trials have shown that pozdeutinurad is not only effective compared to standard of care treatments but also boasts a promising safety profile. In Phase 2 studies, the drug demonstrated notable efficacy, including achieving complete tophi resolution in some patients during the Phase 2b clinical investigation.

The company is currently advancing pozdeutinurad into a pivotal Phase 3 clinical program, further solidifying its commitment to enhancing gout management and improving patient outcomes.

Looking Ahead

With the upcoming presentations at EULAR 2025, Arthrosi is poised to spotlight the capabilities of pozdeutinurad, reinforcing its position as a leader in innovative gout therapies. The medical community will closely watch the findings, hopeful for advancements that could revolutionize how gout is treated and foster improved patient quality of life.

As the event draws near, the anticipation surrounding Arthrosi's contributions and research is palpable, marking a significant moment in the fight against gout. Stakeholders and healthcare professionals alike look forward to the insights that will be shared, contributing to ongoing dialogues about effective gout management.

• ---

For more information about Arthrosi Therapeutics and its initiatives, or to schedule interviews with company representatives, please contact:

• - Media Contact: Shunqi Yan, PhD, Chief Operating Officer
• - Investor Contact: Alex Lobo, Precision AQ